Hosted on MSN13d
Oxford BioTherapeutics and Roche link on antibody cancer treatments
Oxford BioTherapeutics (OBT) has entered a multi-year partnership with Roche to discover antibody-based therapeutics for ...
Fierce Biotech14d
Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
Roche, which put billions on the line a year ago across several ADC pacts, kicked off 2025 by returning to Innovent Biologics ...
PMLive12d
Roche and Oxford BioTherapeutics enter oncology partnership worth over $1bn
Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...
pharmaphorum14d
Roche taps Oxford BioTherapeutics for cancer drug discovery
Oxford BioTherapeutics (OBT) has lined up another big pharma partner for its drug discovery platform, agreeing to work with ...
Contract Pharma12d
Roche & Oxford BioTherapeutics Partner on Novel Cancer Therapies
Oxford BioTherapeutics has partnered with Roche to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer.
Pharmabiz13d
Oxford BioTherapeutics inks multi-year collaboration with Roche to discover novel targets for antibody-based therapeutics to treat cancer
Oxford BioTherapeutics inks multi-year collaboration with Roche to discover novel targets for antibody-based therapeutics to treat cancer: Oxford, UK Thursday, March 20, 2025, 17: ...
BioSpace14d
Roche Ups ADC Bet With $1B in Biobucks for Oxford BioTherapeutics
Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...
The Pharma Letter24y
Roche partners with OBT on novel immuno-oncology targets
UK biotech Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (I-O) and antibody drug conjugate (ADC)-based therapies, today announced a multi-year ...